Higher Mitochondrial DNA Copy Number is Associated with Metformin-Induced Weight Loss

Jing Wang,Hua Liang,Rong Huang,Xiong Weng,Li Zheng,You Wang,Xueying Zheng,Zhenglong Gu,Fei Chen,Jian Shao,Zhaoxu Geng,Ewan R. Pearson,Jianping Weng,Wenying Yang,Tao Xu,Kaixin Zhou
DOI: https://doi.org/10.1038/s43856-023-00258-0
2023-01-01
Communications Medicine
Abstract:Background Considerable variability exists in response to metformin with few effective biomarkers to guide the treatment. Here we evaluated whether whole blood derived mitochondrial DNA copy number (mtDNA-CN) is a biomarker of metformin response as measured by glucose reduction or weight loss. Methods Using data from the trial of Metformin ( n = 304) and AcaRbose ( n = 300) in Chinese as the initial Hypoglycaemic treatment (MARCH), we examined the association between mtDNA-CN and two metformin response outcomes of HbA1c reduction and weight loss. The acarbose arm was used as a comparator group. Whole blood mtDNA-CN was estimated by deep whole genome sequencing with adjustments for confounders. Multiple linear regression and repeated measurement analyses were used to evaluate the association between mtDNA-CN and drug response outcomes. Results Here we show that glucose reduction is not significantly associated with mtDNA-CN and in either treatment arm. In the metformin arm, each increase of 1 SD in mtDNA-CN is significantly ( P = 0.006) associated with a 0.43 kg more weight loss. Repeated measurement analysis shows that after 16 weeks of metformin monotherapy, patients in the top tertile of mtDNA-CN consistently lost 1.21 kg more weight than those in the bottom tertile ( P < 0.001). In comparison, mtDNA-CN is not significantly associated with acarbose-induced weight loss. Conclusions Patients with higher mtDNA-CN are likely to lose more weight upon metformin treatment, suggesting mtDNA-CN as a potential novel biomarker for more effective weight management in type 2 diabetes.
What problem does this paper attempt to address?